Trinity Life Sciences Institutes a Formal Cell and Gene Therapy Center of Excellence
18 Dec 2023
ImmunotherapyCell TherapyGene Therapy
Preview
Source: Business Wire
'Trinity launched the C&GT COE to support clients in a uniquely cross-functional way, so that we can share learnings from our depth of exposure and breadth of experience across client organizations and throughout the lifecycle.'
Preview
Source: Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy (C>) Center of Excellence (COE) that supports life sciences companies in successfully commercializing a C> asset. The unique challenges and opportunities in commercializing C> are markedly different from traditional one-size-fits-all products, requiring innovation and a change in the traditional commercial model.
To enable true commercialization optimization in the C> space, there are several areas with C> nuances that need to be considered:
Operational Model Efficiencies
Specialized Manufacturing & Supply Chain Logistics
Market Access Complexity
Unique Go-To-Market Strategies
Patient Centricity
Life Cycle Management
Trinity’s C> COE provides global partnership to life sciences companies and other service providers in the value chain through advisory services powered by a dedicated team of experts with extensive C> commercialization and disease area expertise. Clients are able to leverage expert support and analytical depth, no matter where they are in the commercialization journey. Advisory project examples include:
- Comprehensive situation analysis as a foundation for a gene therapy
- Launch management activities in preparation to commercialize a cell therapy product
- Opportunity evaluation and business development decision support for gene therapies
- Understanding of current market dynamics, potential peak share and value drivers for a novel product
- Modeling of potential Health Care Professionals (HCP) uptake, pricing opportunities and size of the eligible populations for a gene therapy forecast
- And much more
“Trinity is patient first—and every challenge in C> commercialization has the added impetus of patients waiting for life-changing therapies,” explains Herman Sanchez, Chief Business Officer at Trinity Life Sciences. “Understanding and resolving those problems have become table stakes with C> assets. As these treatments may be curative or first on the market, that work is especially meaningful and impactful.”
“After years of experiencing industry challenges firsthand while commercializing gene therapies, I understand the value of strategic partners who are experienced in C> and have supported manufacturers along the challenges commercialization presents,” explained Keren Shani, Executive Director and Head of Cell & Gene Therapy at Trinity Life Sciences. “Trinity launched the C> COE to support clients in a uniquely cross-functional way, so that we can share learnings from our depth of exposure and breadth of experience across client organizations and throughout the lifecycle.”
A new white paper, Empowering Cancer Immunotherapy: Unleashing the Potential of NK Cell Therapies in Oncology, delivers an overarching assessment of the Natural Killer (NK) cell therapy space with a background on NK-based technology, current clinical development—and ultimately, the value proposition NK cell therapies hold in order to equip readers with the necessary knowledge to drive informed decision-making and potential investment in the space.
Life sciences executives can access the white paper here.
An on-demand webinar, Gene Therapy Uptake: The Elephant in the Room, evaluates the factors that are unique to forecasting gene therapy markets and discusses what companies need to know to maximize their revenue potential. Among other topics, viewers will hear potential pricing strategies to consider—as well as key market drivers and product factors contributing to gene therapy opportunity.
Life sciences executives can view the webinar here.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With over 25 years of experience, Trinity is committed to revolutionizing the commercial model by providing exceptional levels of service, powerful tools and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.